Jeko-1 CDX Model

The Jeko-1 cell line originates from human mantle cell lymphoma (MCL), a unique subtype of non-Hodgkin lymphoma marked by its aggressive clinical course and association with the characteristic t(11;14) chromosomal translocation. This translocation leads to overexpression of the cyclin D1 protein, a hallmark of MCL. Jeko-1 serves as a pivotal tool in understanding MCL’s intricate biology, pathogenesis, and in evaluating therapeutic modalities. This cell line encapsulates many of the molecular and genetic signatures emblematic of MCL, reinforcing its critical role in preclinical studies. The in vitro and in vivo characteristics of Jeko-1 present insights into MCL’s rapid proliferation, potential metastatic patterns, and treatment responses. Researchers leverage the Jeko-1 model to dissect the molecular underpinnings of MCL, evaluate the efficacy of targeted therapies, and develop novel strategies to combat this aggressive lymphoma.

Model Details

Cancer Location: Intravenous
Cancer Type: Mantle Cell Lymphoma
Model Name: Jeko-1
Mouse Strain: CIEA NOG, CB.17 SCID
Treatment Data Available: Chemotherapy (Ibrutinib, Venetoclax, Velcade)

JeKo-1 Growth curves

Jeko-1 CDX Model

Growth of subcutaneous JeKo-1 in CIEA NOG mice (n=5 mice)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.